ARK Investment Management LLC, more commonly known as ARK Invest, is an American investment management firm headquartered in ...

CRISPR Therapeutics is a company that already has a product on the market, yet its market capitalization is only $4.2 billion, about $2 billion lower than Viking's. Axsome Therapeutics, another ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...

In this study, the investigators used the CRISPR gene editing tool to delete various genetic sequences, and identified about ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...

EST Cathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size.

Using CRISPR, the popular gene-editing tool, scientists bumped up the fruit’s sugar content by 30 percent without sacrificing ...